<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053855</url>
  </required_header>
  <id_info>
    <org_study_id>19CH048</org_study_id>
    <secondary_id>2019-A01408-49</secondary_id>
    <nct_id>NCT04053855</nct_id>
  </id_info>
  <brief_title>Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma</brief_title>
  <acronym>PEP-C</acronym>
  <official_title>Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clear cell renal cell carcinoma is diagnosed by imaging, sometimes associated with biopsy.
      This diagnosis is expensive, invasive and sometimes late. The development of a simple
      biological test for diagnosis is essential. Exosomes are 30 to 150 nm membrane vesicles
      secreted into the extracellular space by various living cells. These exosomes can be isolated
      from biological fluids, including urine. The recent study of urinary exosomes is a promising
      topic for analyzing tumor markers in urine. The investigator's goal is to develop a reliable
      technique for detecting tumor exosomes in urine in patients with clear cell renal cell
      carcinoma. The analysis of urinary exosomes could provide a new liquid biopsy tool for the
      early diagnosis of clear cell renal cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to detect urinary exosomes, by electron microscopy technique, from
      clear cell renal cell carcinoma due to exosome markers (CD9) and clear cell kidney cancer
      (CA9).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients (with clear cell kidney cancer) with CD9+ and CA9+ exosomes by electron microscopy technique</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in electron microscopy technique of urinary sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+ /CA9+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in electron microscopy technique of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+ /CA9+ exosomes by electron microscopy technique (%) for control patients</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in electron microscopy technique of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+ /CA9+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in flow cytometry of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+ /CA9+ exosomes by flow cytometry (%) for control patients</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in flow cytometry of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+ /CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+ /CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in electron microscopy technique of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by electron microscopy technique (%) for control patients</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in electron microscopy technique of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in flow cytometry of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by flow cytometry (%) for control patients</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in flow cytometry of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer</measure>
    <time_frame>Years: 2</time_frame>
    <description>Measured by analysis in Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients</measure>
    <time_frame>Years: 2</time_frame>
    <description>Measured by analysis in Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/VGEFR2+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in electron microscopy technique of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/VGEFR2+ exosomes by electron microscopy technique (%) for control patients</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in electron microscopy technique of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/VGEFR2+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in flow cytometry of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/VGEFR2+ exosomes by flow cytometry (%) for control patients</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in flow cytometry of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/VGEFR2+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) of urinary sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD9+/VGEFR2+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients</measure>
    <time_frame>At inclusion</time_frame>
    <description>Measured by analysis in Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) of urinary sample.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Renal mass patients</arm_group_label>
    <description>Patients with renal mass requiring surgery (partial or total nephrectomy) will be included.
They will have an urinary sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <description>Control patients (without renal mass) will be included. They will have an urinary sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Urinary sample</intervention_name>
    <description>Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.</description>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_label>Renal mass patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urinary sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        60 patients and 40 control will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients:

          -  All patients with renal mass requiring surgery (partial or total nephrectomy)

          -  Social security affiliation

          -  Signed informed consent

        Control :

          -  Patients hospitalized in the urology department without cancer and without known renal
             mass

          -  Unscheduled nephrectomy

          -  Social security affiliation

          -  Signed informed consent

        Exclusion Criteria:

          -  Insufficient volume of urine sample (&lt; 100 ml)

          -  Patients with a urinary catheter

          -  Patients under court-ordered guardianship or curators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas MOTTET, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nora MALLOUK, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UNIVERSITY SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guorong LI, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU DE SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas MOTTET, MD PhD</last_name>
    <phone>(0)477828331</phone>
    <phone_ext>+33</phone_ext>
    <email>nicolas.mottet@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnauld GARCIN, CRA</last_name>
    <phone>(0)477120286</phone>
    <phone_ext>+33</phone_ext>
    <email>Arnauld.Garcin@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas MOTTET, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hocine HABCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clear cell renal cell carcinoma</keyword>
  <keyword>Urinary exosomes</keyword>
  <keyword>Detection</keyword>
  <keyword>Electron microscopy technique</keyword>
  <keyword>Flow cytometry</keyword>
  <keyword>RT-qPCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

